Product Name: Abaloparatide
Form: Free base
CAS No: 247062-33-5
Molar Mass: 3960.59
Chemical Formula: C174H300N56O49
Synonyms: BA 058, BIM 44058, Eladynos
Storage: Store at -20℃
Sequence: AVSEHQLLHD KGKSIQDLRR RELLEKLLXK LHTA
Target: PTHR1
Application:
Abaloparatide (CAS: 247062-33-5) is a notable pharmaceutical compound designed for the treatment of osteoporosis, particularly in postmenopausal women at an increased risk of fractures. Functioning as a parathyroid hormone-related protein (PTHrP) analog, abaloparatide stimulates bone formation by promoting osteoblast activity and increasing bone mineral density. Its mechanism involves selective activation of the PTH1 receptor, resulting in enhanced bone-building processes without a significant impact on bone resorption. By offering a balanced approach to bone remodeling, abaloparatide helps mitigate the risk of fractures effectively. This targeted intervention in bone metabolism positions abaloparatide as a valuable addition to pharmaceutical strategies, addressing the specific needs of individuals facing osteoporosis-related challenges and promoting skeletal health.
Current Research:
Abaloparatide is a synthetic analog of human parathyroid hormone-related protein (PTHrP), used in the treatment of osteoporosis. It is specifically indicated for postmenopausal women at high risk of fracture. Abaloparatide works by stimulating bone formation through activation of the parathyroid hormone receptor 1 (PTH1R), promoting osteoblast activity, and enhancing bone mineral density (BMD). As an anabolic (bone-building) therapy, abaloparatide is particularly effective in individuals with severe osteoporosis or those who have failed other treatments. This drug offers a potent alternative to traditional osteoporosis treatments, aiming to reduce the risk of vertebral and non-vertebral fractures.
Mechanism of Action
Abaloparatide mimics the action of parathyroid hormone-related protein (PTHrP), a naturally occurring protein that plays a key role in bone metabolism. It binds to and activates the PTH1R receptor on osteoblasts, promoting their differentiation and activity, leading to increased bone formation. Unlike traditional therapies that primarily inhibit bone resorption, abaloparatide stimulates both osteoblasts (bone-building cells) and inhibits osteoclasts (bone-resorbing cells), resulting in increased bone mass and improved bone strength. Its ability to promote anabolic bone activity helps to counteract the bone loss seen in osteoporosis, especially in patients at high fracture risk.
Indications and Uses
Abaloparatide is approved for the treatment of osteoporosis in postmenopausal women who are at high risk of fractures. It is especially beneficial for individuals with low bone mineral density and a history of fractures, or those who have failed to respond to other osteoporosis medications. Abaloparatide is administered via a daily subcutaneous injection and typically used for a duration of up to 24 months. After this initial period, patients may transition to other therapies such as bisphosphonates to maintain the improved bone density achieved with abaloparatide.
Efficacy and Clinical Benefits
Abaloparatide has been shown to significantly increase bone mineral density (BMD) in patients with osteoporosis, particularly in the spine and hip. Clinical trials have demonstrated that treatment with abaloparatide leads to a substantial reduction in the risk of vertebral and non-vertebral fractures. The drug’s anabolic effects on bone formation lead to a faster improvement in BMD compared to other treatments like bisphosphonates, which focus on inhibiting bone resorption. Abaloparatide’s ability to stimulate new bone growth and strengthen existing bone makes it a potent option for patients with severe osteoporosis and those at high fracture risk.
Safety and Tolerability
Abaloparatide is generally well tolerated, but like all medications, it can cause some side effects. The most common adverse reactions include injection site reactions, dizziness, nausea, and headache. A rare but serious side effect is osteosarcoma, a type of bone cancer, which was observed in animal studies. As a result, abaloparatide is contraindicated in patients with a history of bone cancer or skeletal metastasis. There are also potential risks related to hypercalcemia (elevated blood calcium levels), which requires monitoring during treatment. Patients should be monitored for symptoms of hypercalcemia and calcium levels should be regularly checked. Other potential concerns include the risk of kidney stones and changes in blood pressure, so regular monitoring of renal function and cardiovascular health is recommended.
Advantages and Limitations
Abaloparatide’s main advantage is its ability to promote bone formation rather than merely inhibiting resorption, which distinguishes it from other osteoporosis treatments like bisphosphonates and denosumab. It is particularly beneficial for individuals with severe osteoporosis or those at high fracture risk. However, its use is limited to 24 months due to concerns about the potential risk of osteosarcoma. After this period, patients typically transition to other medications to maintain bone health. The need for daily injections may also affect patient compliance, though this can be mitigated by education and support from healthcare providers.
Future Directions
Ongoing research is exploring the long-term effects and potential expanded applications of abaloparatide. Studies are examining its use in combination with other therapies to further improve bone density and reduce fracture risk. Additionally, there is growing interest in understanding the broader implications of abaloparatide’s ability to stimulate bone formation, including its potential use in conditions such as bone healing after fractures or in other metabolic bone diseases. Investigations into new delivery methods or less frequent dosing regimens are also underway to improve patient convenience and adherence.
Reference:
Get a Quote
LinkPeptide
